Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Depreciation & Amortization (CF): 2017-2025

Historic Depreciation & Amortization (CF) for Dianthus Therapeutics (DNTH) over the last 6 years, with Sep 2025 value amounting to $27,000.

  • Dianthus Therapeutics' Depreciation & Amortization (CF) rose 8.00% to $27,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $110,000, marking a year-over-year increase of 22.22%. This contributed to the annual value of $96,000 for FY2024, which is 43.28% up from last year.
  • Dianthus Therapeutics' Depreciation & Amortization (CF) amounted to $27,000 in Q3 2025, which was down 10.00% from $30,000 recorded in Q2 2025.
  • Dianthus Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $511,000 during Q1 2022, with a 5-year trough of $15,000 in Q2 2023.
  • For the 3-year period, Dianthus Therapeutics' Depreciation & Amortization (CF) averaged around $59,545, with its median value being $25,000 (2024).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first crashed by 96.86% in 2023, then skyrocketed by 53.33% in 2024.
  • Dianthus Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $466,000 in 2022, then crashed by 95.71% to $20,000 in 2023, then skyrocketed by 30.00% to $26,000 in 2024, then climbed by 8.00% to $27,000 in 2025.
  • Its last three reported values are $27,000 in Q3 2025, $30,000 for Q2 2025, and $27,000 during Q1 2025.